Accessibility Menu
Eli Lilly logo

Eli Lilly(NYSE) LLY

Market Cap$1.18TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1970)+206,827%
5 Year+395%
1 Year+76%
1 Month+4%
Premium Feature
Moneyball Superscore
89/100
$1,250.33
-0.40%
-5.07Today
After hours$1,249.51-$0.83 (-0.07%)
Eli Lilly last closing stock price
MetricPriceDate
Last closeUSD 1,246.932026-08-24
Eli Lilly stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.39%USD 1,183.162026-08-17
1 month+4.41%USD 1,194.322026-07-24
3 month+17.28%USD 1,063.222026-05-26
Year to date+16.59%USD 1,069.512025-12-31
1 year+76.31%USD 707.222025-08-22
3 year+129.91%USD 542.362023-08-25
5 year+394.5%USD 252.162021-08-25
Since inception+206,826.59%USD 0.611970-07-09

Eli Lilly Financials at a Glance

Market Cap

$1.18TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$79.67B

Net Income (TTM)

$26.71B

EPS (TTM)

$29.43

P/E Ratio

42.66

Dividend

$6.69

Beta (Volatility)

0.58 (Low)

Price

$1,250.33

Volume

1,665,577.575

Open

$1,262.14

Previous Close

$1,246.93

Daily Range

$1,230.95 - $1,262.14

52-Week Range

$694.23 - $1,292.65

Estimated Earnings Date

Oct 29, 2026

LLY News

Ken Griffin_Citadel_Founder & CEO_imageSource_Getty Images

Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?

Keith SpeightsAug 23, 2026
Fool - eli lilly LLY

Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Selena MaranjianAug 21, 2026
A person trying to lose weight and who is measuring their waist.

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?

David Jagielski, CPAAug 19, 2026
Blue poker chips on stock market background.jpg

How to Invest in Vanguard Morningstar Mega-Cap Growth ETF (MGK)

Tony DongAug 17, 2026
AI chatbot

Can You Invest in Anthropic Pre-IPO? Here's What You Need to Know

Matt DiLalloAug 17, 2026
Eli Lilly logo

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

Prosper Junior BakinyAug 15, 2026
Pills-in-a-dollar-sign.jpg

4 Best Pharmaceutical Stocks for 2026 and How to Invest

Keith SpeightsAug 14, 2026
GettyImages-1446718548

Eli Lilly Just Scored a European Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Matthew BenjaminAug 14, 2026
Page 1

LLY: Motley Fool Moneyball Superscore

89

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eli Lilly

Eli Lilly and Company makes medicines for people with serious illnesses. These drugs help patients manage diabetes, obesity, and cancer. The company sells these treatments to healthcare providers globally.

Medicines and Modern Health

  • Incretin Medicines: Treatments like Mounjaro and Zepbound that mimic hormones to manage weight and blood sugar; accounted for 65% of revenue for the six months ended June 30, 2026.
  • Oncology Portfolio: Medicines targeting various cancers, such as Verzenio for breast cancer and Alimta for lung cancer.
  • Diabetes Care: Treatments including Jardiance for type 2 diabetes and various insulin products like Humalog.
  • Immunology and Neuroscience: Drugs addressing autoimmune conditions and mental health, such as Taltz for plaque psoriasis and Cymbalta for depression.

Growing Through Strategic Deals

  • Launched Foundayo in the U.S. during the second quarter of 2026 to treat obesity.
  • Invested $13.3 billion in 2026 for acquisitions of biotechnology firms including Orna and Ajax.
  • Paid $2.0 billion in July 2026 to acquire companies for building an infectious disease portfolio.
  • Initiated significant manufacturing expansion projects to meet the demand for cardiometabolic health products.

Science and Scale

Lilly focuses on developing new molecular entities, which are unique drug compounds created to treat specific diseases. The company uses a global manufacturing network to produce and distribute these treatments to patients and healthcare systems.

Recent Financial Results

  • Revenue was $23.0 billion for the three months ended June 30, 2026, up 48% year over year.
  • Net income rose to $14.5 billion during the six months ended June 30, 2026, up 72% year over year.
  • The company held $9.0 billion in cash and cash equivalents as of June 30, 2026.
  • Market capitalization was $1.1 trillion as of the second quarter of 2026.

Bottom Line

Lilly has shifted its focus toward high-growth incretin medicines while expanding its clinical pipeline through strategic acquisitions. This transition reinforces its position in the competitive global pharmaceutical market.

AI Generated • Aug 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

50,000

CEO

David A. Ricks, MBA

Website

www.lilly.com

Headquarters

Indianapolis, IN 46285, US

LLY Financials

Key Financial Metrics (TTM)

Gross Margin

84.01%

Operating Margin

43.92%

Net Income Margin

33.53%

Return on Equity

92.58%

Return on Capital

43.01%

Return on Assets

18.77%

Earnings Yield

2.34%

Dividend Yield

0.53%

Payout Ratio

21.66%

Stock Overview

Market Cap

$1.18TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

941.36M

Volume

1.67M

Avg. Volume

2.98M

Financials (TTM)

Gross Profit

$66.93B

Operating Income

$34.99B

EBITDA

$35.21B

Operating Cash Flow

$28.08B

Capital Expenditure

-$8.03B

Free Cash Flow

$20.05B

Cash & ST Invst.

$8.95B

Total Debt

$54.91B

Eli Lilly Performance Analysis

Eli Lilly annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 28,541,400,0000.8%
20232023-12-31USD 34,124,100,00019.6%
20242024-12-31USD 45,042,700,00032.0%
20252025-12-31USD 65,179,000,00044.7%
Eli Lilly sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.1%
Q42025-12-319.6%
Q12026-03-312.6%
Q22026-06-3016.0%
Eli Lilly annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 6.9012.8%
20232023-12-31USD 5.80-16.0%
20242024-12-31USD 11.71101.9%
20252025-12-31USD 22.9595.9%
Eli Lilly sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.3%
Q42025-12-3119.0%
Q12026-03-3111.8%
Q22026-06-30-3.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$22.97B

+47.7%

Gross Profit

$19.71B

+50.3%

Gross Margin

85.78%

N/A

Market Cap

$1.18TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$23.64M

N/A

Employees

50,000

N/A

Net Income

$7.10B

+25.3%

EBITDA

$9.25B

+23.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$8.95B

+152.4%

Total Debt

$54.91B

+37.6%

Accounts Receivable

$23.48B

+36.4%

Inventory

$16.79B

+52.5%

Long Term Debt

$47.86B

+40.0%

Short Term Debt

$7.05B

+23.2%

Return on Assets

18.77%

N/A

Return on Invested Capital

37.01%

N/A

Free Cash Flow

$7.76B

+504.6%

Operating Cash Flow

$10.69B

+246.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JNJJohnson & Johnson
$273.04+1.04%
ABBVAbbVie Inc.
$264.52-0.17%
MRKMerck & Co., Inc.
$150.69-1.22%
NVSNovartis AG
$158.02-0.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$208.48-0.03%
BITOProShares Trust - ProShares Bitcoin ETF
$10.63+0.02%
INTCIntel
$87.26-0.03%
IBITiShares Bitcoin Trust
$44.64+0.02%

Questions About LLY

What is the current price of Eli Lilly?

Eli Lilly is trading at $1,246.93 per share.

What is the 52-week range for Eli Lilly?

Over the past 52 weeks, Eli Lilly has traded between $694.23 and $1,292.65.

How much debt does Eli Lilly have?

As of the most recent reporting period, Eli Lilly reported total debt of $54.91B.

How much cash does Eli Lilly have on hand?

Eli Lilly reported $8.89B in cash and cash equivalents in its most recent financial results.

What is Eli Lilly’s dividend yield?

Eli Lilly currently has a dividend yield of 0.53%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services